Anti-PD-1 and Anti-PDL-1 monoclonal antibodies causing type 1 diabetes

Diabetes Care

Volumn 38, Issue 9, 2015, Pages e137-e138

  Mellati, Mahnaz ^a   Eaton, Keith D ^b   Brooks Worrell, Barbara M ^a,c   Hagopian, William A ^a,d   Martins, Renato ^b   Palmer, Jerry P ^a,c   Hirsch, Irl B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C PEPTIDE; HEMOGLOBIN A1C; METFORMIN; MONOCLONAL ANTIBODY; PROGRAMMED CELL DEATH LIGAND 1 MONOCLONAL ANTIBODY; PROGRAMMED CELL DEATH PROTEIN 1 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; AGED; AUTOIMMUNITY; CANCER MORTALITY; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DISEASE MODEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN DEPENDENT DIABETES MELLITUS; LUNG ADENOCARCINOMA; MALE; NONOBESE DIABETIC MOUSE; NOTE; SARCOMATOID SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CASE REPORT; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; JAW NEOPLASMS; LUNG NEOPLASMS;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CARCINOMA, SQUAMOUS CELL; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; JAW NEOPLASMS; LUNG NEOPLASMS; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84962440790     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0889     Document Type: Note

References (5)

1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti- PD-1 antibody in cancer. N Engl J Med 2012;366: 2443-2454.
2. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in non obese diabetic (NOD) mice. J Exp Med 2003;198:63-69.
3. Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015;38:e55-e57.
4. Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 2015;64:765-767.
5. Goel A, Chiu H, Felton J, Palmer JP, Brooks- Worrell B. T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe b-cell lesions in phenotypic type 2 diabetes. Diabetes 2007;56:2110-2115.